Clinical Study

Ms200095-0022- A Phase II Single-Arm Trial To Investigate Tepotinib In Stage IIIb/Iv Adenocarcinoma Of The Lung With Met Exon 14 (Metex14) Skipping Alterations After Failure Of At Least One Prior Active Therapy, Including A Platinum-Doublet-Containing Reg

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to learn how effective the study drug, tepotinib, is at stopping the growth and spread of lung cancer that did not respond to previous treatment with a specific type of chemotherapy. This study will also measure the safety of the study drug and the side effects.

Criteria:

To Be Eligible: Must Have Confirmed Stage Iiib/Iv Nsclc, Age 18 Or Older, Nonpregnant And Nonbreastfeeding, No Prior Chemo, Radiation Or Hormonal Therapy Within 21 Days

Keywords:

Lung Cancer, Adenocarcinoma, Cancer, Phase Ii

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.